Court rules against Sanofi's Lovenox in Amphastar, Teva challenge

02/11/2007 | Bloomberg Businessweek · Wall Street Journal, The

A U.S. court cleared the way for a generic version of Lovenox, a Sanofi-Aventis blood thinner, when it ruled the firm engaged in inequitable conduct for its original patent. Sanofi, which may appeal the verdict, has a patent that does not expire until 2012, but Amphastar Pharmaceuticals and Teva Pharmaceutical Industries sued to be able to sell generics before then, even though no generic copy has been approved by the FDA.

View Full Article in:

Bloomberg Businessweek · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX